gms | German Medical Science

29. Wissenschaftlicher Kongress der Deutschen Hochdruckliga

Deutsche Hochdruckliga e. V. DHL ® - Deutsche Hypertonie Gesellschaft Deutsches Kompetenzzentrum Bluthochdruck

23. bis 25.11.2005, Berlin

Olmesartan medoxomil for the treatment of hypertension under daily-practice conditions – results of a post-authorization study

Olmesartan medoxomil zur Behandlung der Hypertonie unter Alltagsbedingungen - Ergebnisse einer Anwendungsbeobachtung

Meeting Abstract

Search Medline for

  • J. Scholze - Universitätsklinikum Charité Berlin (Berlin, D)
  • S. Ewald - Sankyo Pharma GmbH (München, D)

Hypertonie 2005. 29. Wissenschaftlicher Kongress der Deutschen Hochdruckliga. Berlin, 23.-25.11.2005. Düsseldorf, Köln: German Medical Science; 2006. Doc05hochP81

The electronic version of this article is the complete one and can be found online at:

Published: August 8, 2006

© 2006 Scholze et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



Aim of the Study: This post-authorization study assessed the efficacy, safety, and tolerability of the treatment with olmesartan medoxomil in patients with hypertension under daily practice conditions in Germany.

Patients and Methods: A total of 11,959 patients were included in 3,426 clinical practices. Patients received 10, 20, or 40 mg of olmesartan medoxomil, which could be up- and down-titrated if necessary. Efficacy, safety, and tolerability data were collected at 2 follow-up visits scheduled after approximately 4-8 and 12 weeks. Patient data were documented using standardized case report forms. The data were analyzed descriptively and exploratively.

Results: Mean treatment duration was 12.8 weeks. At the end of the observation period, mean blood pressure reduction was 28.4/14.2 mmHg, 80.9% of patients had a diastolic blood pressure <90 mmHg or a decrease of diastolic blood pressure by >=10 mmHg ("responders"), and 64.3% had a diastolic blood pressure <90 mmHg ("normalizers"). At endpoint, 68.8% of patients were receiving 20 mg, 16.3% 10 mg, and 11.2% were taking 40 mg olmesartan medoxomil. Blood pressure amplitude decreased from 70.2 mmHg to 56.0 mmHg.

A total of 4,676 patients (39.1%) received additional antihypertensive medications, of which beta blockers (21.7%) and diuretics (20.4%) were most commonly used.

140 patients (1.2%) experienced a total of 240 adverse drug reactions. Subjective physicians' assessments of efficacy, tolerability, and patient compliance of olmesartan medoxomil treatment had ratings of "very good" and "good" in 92.1% (efficacy), 97.7% (tolerability), and 94.9% (patient compliance) of cases.

Conclusions: Olmesartan medoxomil proved to be effective and well-tolerated for the treatment of 11,959 patients with hypertension. The excellent efficacy of the drug is in particular supported by the high rate (64.3%) of patients with normal diastolic blood pressure at the end of the observation period.